Data availability
All data and/or supporting documents related to the paper that Nature reviewers and/or editors will request for the purposes of evaluating this paper and verifying its contents will be provided through Egnyte system, at any time. Data will also be available to researchers and/or scientists in alignment with the International Committee of Medical Journal Editors’ policy on clinical data sharing. Specifically, the authors will provide access to individual deidentified participant-level data that underlie the data presented in this paper, including data dictionaries, the study protocol and other relevant information, to any researcher who provides a methodologically sound proposal for academic purposes beginning 6 months and ending 5 years after article publication. These data can be requested via email to iritg@biolinerx.com, and will be made available to requesting parties through the Egnyte system following approval. This request and availability mechanism for accessing the clinical dataset will similarly apply to requests for the ‘minimum dataset’ necessary to interpret, verify and extend the research in the article. All requests for clinical data will be reviewed by the sponsor (BioLineRx) to verify whether the request is subject to any intellectual property or confidentiality obligations. The gene count matrices for scRNA-seq are available via Gene Expression Omnibus (accession no. 